The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Anupam B. Jena & John E. Calfee & Edward C. Mansley & Tomas J. Philipson, 2009. ""Me-Too" Innovation in Pharmaceutical Markets," NBER Chapters,in: Frontiers in Health Policy Research, volume 12 National Bureau of Economic Research, Inc.
- de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges, 2013.
"Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?,"
Journal of Health Economics,
Elsevier, vol. 32(1), pages 268-285.
- de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges, 2010. "Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?," CEPR Discussion Papers 8076, C.E.P.R. Discussion Papers.
- Regan, Tracy L., 2008.
"Generic entry, price competition, and market segmentation in the prescription drug market,"
International Journal of Industrial Organization,
Elsevier, vol. 26(4), pages 930-948, July.
- Tracy L. Regan, 2007. "Generic entry, price competition, and market segmentation in the prescription drug market," Working Papers 2010-7, University of Miami, Department of Economics.
- Dhaval Dave & Henry Saffer, 2012. "Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand," Southern Economic Journal, Southern Economic Association, vol. 79(1), pages 97-126, July.
- Sotiris Vandoros & Panos Kanavos, 2013. "The generics paradox revisited: empirical evidence from regulated markets," Applied Economics, Taylor & Francis Journals, vol. 45(22), pages 3230-3239, August.
- Rizzo, John A, 1999. "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs," Journal of Law and Economics, University of Chicago Press, vol. 42(1), pages 89-116, April.
More about this item
KeywordsAsymmetric competition; Generic entry; Pharmaceutical industry;
- D22 - Microeconomics - - Production and Organizations - - - Firm Behavior: Empirical Analysis
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- L13 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Oligopoly and Other Imperfect Markets
NEP fieldsThis paper has been announced in the following NEP Reports:
- NEP-ALL-2017-02-12 (All new papers)
- NEP-COM-2017-02-12 (Industrial Competition)
- NEP-HEA-2017-02-12 (Health Economics)
- NEP-IND-2017-02-12 (Industrial Organization)
- NEP-INO-2017-02-12 (Innovation)
- NEP-IPR-2017-02-12 (Intellectual Property Rights)
- NEP-MKT-2017-02-12 (Marketing)
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cpr:ceprdp:11813. See general information about how to correct material in RePEc.